Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Development of a Device to Measure Dark Adaptation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr Jeremiah Kelly, University of Manchester
ClinicalTrials.gov Identifier:
NCT02090751
First received: March 12, 2014
Last updated: July 4, 2016
Last verified: July 2016

March 12, 2014
July 4, 2016
July 2014
February 2015   (Final data collection date for primary outcome measure)
The rate of recovery of the rod phase S2 [ Time Frame: At participant visit only ]
Dark adaptation will be measured in 40 participants; 20 healthy and 20 with early macular disease. This index of retinal health will be analysed for its sensitivity and specificity for the identification participants with macular disease.
Same as current
Complete list of historical versions of study NCT02090751 on ClinicalTrials.gov Archive Site
  • Lifestyle questionnaire [ Time Frame: At participant visit only. ]
    We have a simple questionnaire to investigate factors reported in the literature to have an effect on macular health. We will use the categorical data collected by the questionnaire to assess the influence of these lifestyle measures on the index of retinal health found from the dark adaptation measurement.
  • Participant Experience Questionnaire [ Time Frame: Within one month of participant visit. ]
    We will give each participant a questionnaire when they finish their visit and will ask for their experience of the process of dark adaptation measurement.
Same as current
Not Provided
Not Provided
 
Development of a Device to Measure Dark Adaptation
A Study to Evaluate the Sensitivity and Specificity of a Device to Measure Dark Adaptation in Subjects With and Without Early Macular Disease

Age Related Macular Disease (AMD) is easily the leading cause of blindness in older people in developed countries. It affects between 30 and 50 million individuals worldwide, with around 30% of the over 65's showing early signs of the disease. Severe AMD has a devastating impact on the quality of life; it causes extensive visual impairment, making reading difficult and driving impossible. Patients lose their independence and become a major burden on public health systems.

Present treatment options are limited. Many new therapies are under development and all will need evaluation using a test with high specificity and sensitivity for early AMD. The present application will develop such an instrument. The prototype was funded by a previous i4i FS (feasibility study ll-FS-0110-14036). The new device measures sensitivity to a dim flickering light using the same principle as an established european conformity marked (CE marked) instrument. The original method involved lights of different wavelengths and higher intensities.

The instrument in this study assesses night vision, which is selectively damaged in early stage AMD. In low lighting, the investigators vision depends on specialized rod photoreceptors. Cone photoreceptors, which provide daytime vision, remain normal in the early stages of the disease. By the time patients complain of reduced (cone-based) visual acuity, they will have had the disease for many years and lost many thousands of photoreceptors.

In a clinical environment dark adaptation (DA) is measured by exposing the patient to a brief bright light and then measuring their sensitivity to a flickering light. This sensitivity recovery has a typical appearance; an early rapid recovery mediated by the colour vision system (cone photoreceptors) and a slower recovery of the low light system (rod photoreceptors).

If the measurements are made against a black background then a bi exponential model is suitable, however if a dim luminous background is used then the recovery is better modelled by a exponential bi linear model. We will use the exponential bilinear model, which has seven parameters. The parameters are as follows; the exponential cone phase is modelled by the cone threshold, cone coefficient, and cone time constant. The S2 rod phase is modelled by its commencement time. This is the time when the rod system becomes more sensitive than the cone system, sometimes called the cone-rod break point (alpha) and the slope of the subsequent thresholds. The late rod phase (S3) is similarly modelled by a transition time or rod-rod breakpoint (beta) and its slope.

If the initial bright light is sufficiently intense then the recovery of the rod phase (S2) is termed rate limited. There is evidence that this recovery rate is a useful measure of the health of the light sensing layer of the eye an adjoining tissues, the retina, retinal pigment epithelium and choroid. It is these tissues that are thought to be affected in age related macular disease.

In this study we will measure rate of rod recovery sometimes called the S2 phase. We want to see whether this measurement can be used to identify patients with and without early macular disease.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Participants will be recruited from a the greater manchester area by a call for volunteers, through the local newspaper, a university email list and through the Hale Barns Macular Disease Association
  • Macular Degeneration
  • Age-Related Macular Degeneration
Not Provided
  • No Maculopathy
    Aged 50 to 80 with no macular disease
  • Early Maculopathy
    Aged 50 to 80 with early AREDS defined 2,3 age related maculopathy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
April 2015
February 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • They understand their rights as a research Participant and are willing and able to sign a Statement of Informed Consent.
  • They are over 50 years and less than 80 years of age.
  • They are willing and able to perform the experimental task required.
  • They are not a current participant in other studies. Lifestyle factors
  • Diet that includes animal and/or vegetable fats. Health factors
  • Good ocular health, the following will be admitted Pseudophakia, aphakic with good VA (better than 6/12), AMD with AREDS category 1,2,or 3.
  • Good systemic health, the following may be admitted Hypertension Thyroid disease Arthritis Depression
  • Medication, that is not hepatotoxic or retinotoxic directly or by treating a disease that is may be admitted. Use British National Formulary (BNF) to check if unsure.

Exclusion Criteria:

  • Unlikely to be available, willing, and able to attend
  • Unable to give consent.
  • Current participant in other studies.
  • Subject to any condition that may adversely affect fat intake (proxy for Vit A) or retinal function.

Lifestyle factors

  • Diet that excludes animal and/or vegetable fats.

Health factors

  • Ocular Any active disease, e.g. · Glaucoma, Cataract if VA worse than 6/12 · Diabetic Retinopathy · Retinal detachment · Uveitis Treatments · Laser Sx. to cornea, capsule or retina · Recent cataract extraction within 12 weeks · Drops
  • Systemic Diabetes Liver disease, Hepatitis: Past or present Digestive disorders, e.g. Crohns, irritable bowel syndrome (IBS), lactose intolerance Bowel surgery, stomach staple, ileostomy, colostomy Kidney disorder (elevated iron) Chronic alcoholism or drug abuse

    • Medication, hepatotoxic or retinotoxic directly or by treating a disease that is. If unsure use BNF and seek advice of ophthalmologist/study leader. Examples include:
  • Interferon alpha
  • Vitamin A derivatives (Chronic eczema)
  • Amiodarone (Heart disease)
  • Chloroquine/Hydrochloroquine (Plaquenil) (Rheumatoid Arthritis/ Malaria)
  • Tamoxifen (Breast Cancer)
  • Chlorpromazine (Schizophrenia)
  • Deferoxamine (Thalassemia, blood transfusions/ kidney disease)
  • Phenothiazines (Anti-psychotic/epilepsy)
  • Ethambutol (TB)
Sexes Eligible for Study: All
50 Years to 80 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT02090751
II-LB-0712-20001
No
Not Provided
Not Provided
Not Provided
Dr Jeremiah Kelly, University of Manchester
University of Manchester
Not Provided
Principal Investigator: Ian J Murray, PhD University of Manchester
University of Manchester
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP